Marco Canevelli1, Giulia Grande2, Eleonora Lacorte3, Elisa Quarchioni3, Matteo Cesari4, Claudio Mariani2, Giuseppe Bruno5, Nicola Vanacore3. 1. Department of Neurology and Psychiatry, "Sapienza" University of Rome, Italy. Electronic address: marco.canevelli@gmail.com. 2. Center for Research and Treatment on Cognitive Dysfunctions, Biomedical and Clinical Sciences Department, "Luigi Sacco" Hospital, University of Milan, Italy. 3. National Centre for Epidemiology, Surveillance, and Health Promotion, National Institute of Health, Rome, Italy. 4. Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Université de Toulouse III Paul Sabatier, Toulouse, France. 5. Department of Neurology and Psychiatry, "Sapienza" University of Rome, Italy.
Abstract
OBJECTIVES: The issue of subjects with mild cognitive impairment (MCI) reverting to normal cognition (NC) has to date been taken in limited consideration, and no conclusive data are available on the rate of reversion. We aimed at systematically reviewing available longitudinal studies on MCI and meta-analyzing data with the purpose of estimating the proportion of subjects reverting to NC. DESIGN: We performed a systematic bibliographic search on PubMed, the Cochrane Library, and the ISI Web of Science databases. We included in the review all longitudinal studies on MCI published from 1999 up to November 2015. Only studies with a longitudinal design, a follow-up ≥2 years, enrolling subjects with MCI, and reporting the number or the percentage of subjects reverting to NC were included. Data extraction was performed independently by 2 authors. The methodological quality of studies was also assessed by 2 independent authors using the QUIPS tool. RESULTS: Twenty-five studies were included. The quality of evidence was found to be moderate. We observed an overall 18% (95% CI 14-22) reversion rate from MCI to NC. Results from the metaregression showed a significant association between effect size and study setting. In particular, estimates significantly varied according to study setting, with an 8% (95% CI 4-11) reversion rate in clinical-based studies and a 25% (95% CI 19-30) rate in population-based studies. The frequency of reversion from MCI to NC further increased to 26% when considering only studies of better quality. Only a few studies were designed to specifically investigate the reversion from MCI to NC, thus relevant information on this topic was frequently missing. CONCLUSION: Our data confirm that reversion to normality is a common outcome in subjects with MCI, thus leading to recommend a more balanced view when approaching the construct of MCI both in a clinical and in a research setting.
OBJECTIVES: The issue of subjects with mild cognitive impairment (MCI) reverting to normal cognition (NC) has to date been taken in limited consideration, and no conclusive data are available on the rate of reversion. We aimed at systematically reviewing available longitudinal studies on MCI and meta-analyzing data with the purpose of estimating the proportion of subjects reverting to NC. DESIGN: We performed a systematic bibliographic search on PubMed, the Cochrane Library, and the ISI Web of Science databases. We included in the review all longitudinal studies on MCI published from 1999 up to November 2015. Only studies with a longitudinal design, a follow-up ≥2 years, enrolling subjects with MCI, and reporting the number or the percentage of subjects reverting to NC were included. Data extraction was performed independently by 2 authors. The methodological quality of studies was also assessed by 2 independent authors using the QUIPS tool. RESULTS: Twenty-five studies were included. The quality of evidence was found to be moderate. We observed an overall 18% (95% CI 14-22) reversion rate from MCI to NC. Results from the metaregression showed a significant association between effect size and study setting. In particular, estimates significantly varied according to study setting, with an 8% (95% CI 4-11) reversion rate in clinical-based studies and a 25% (95% CI 19-30) rate in population-based studies. The frequency of reversion from MCI to NC further increased to 26% when considering only studies of better quality. Only a few studies were designed to specifically investigate the reversion from MCI to NC, thus relevant information on this topic was frequently missing. CONCLUSION: Our data confirm that reversion to normality is a common outcome in subjects with MCI, thus leading to recommend a more balanced view when approaching the construct of MCI both in a clinical and in a research setting.
Authors: Mary M Machulda; Emily S Lundt; Sabrina M Albertson; Walter K Kremers; Michelle M Mielke; David S Knopman; Mark W Bondi; Ronald C Petersen Journal: Alzheimers Dement Date: 2019-05-23 Impact factor: 21.566
Authors: Michael A Sugarman; Michael L Alosco; Yorghos Tripodis; Eric G Steinberg; Robert A Stern Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Kelsey R Thomas; Joel S Eppig; Alexandra J Weigand; Emily C Edmonds; Christina G Wong; Amy J Jak; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Steven D Edland; Mark W Bondi Journal: Alzheimers Dement Date: 2019-01-11 Impact factor: 21.566
Authors: Annie Robitaille; Ardo van den Hout; Robson J M Machado; David A Bennett; Iva Čukić; Ian J Deary; Scott M Hofer; Emiel O Hoogendijk; Martijn Huisman; Boo Johansson; Andriy V Koval; Maaike van der Noordt; Andrea M Piccinin; Judith J M Rijnhart; Archana Singh-Manoux; Johan Skoog; Ingmar Skoog; John Starr; Lisa Vermunt; Sean Clouston; Graciela Muniz Terrera Journal: Alzheimers Dement Date: 2018-02-01 Impact factor: 21.566
Authors: Mary Ganguli; Yichen Jia; Tiffany F Hughes; Beth E Snitz; Chung-Chou H Chang; Sarah B Berman; Kevin J Sullivan; M Ilyas Kamboh Journal: J Am Geriatr Soc Date: 2018-11-16 Impact factor: 5.562
Authors: Kelsey R Thomas; Emily C Edmonds; Joel S Eppig; Christina G Wong; Alexandra J Weigand; Katherine J Bangen; Amy J Jak; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Steven D Edland; Mark W Bondi Journal: Alzheimers Dement Date: 2019-09-05 Impact factor: 21.566